Increase of serum β2-microglobulin in patients affected by HCV correlated hepatocellular carcinoma

Malaguarnera, Michele; Fazio, Ignazio Di; Ferlito, L.; Pistone, Giovanni; Laurino, A; Vinci, E.; Mazzoleni, Guido

doi:10.1097/00042737-200012080-00014

Cited by 13 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the results might have been obscured by the fact that those two types of neoplasms were analysed together . In adult solid malignancies increased pre-treatment serum B2-M correlated signiWcantly with tumour size in HCV associated hepatocellular carcinoma (Malaguarnera et al 2000) and with stage, histopathologic grade and, similarly to the Wndings of our present study, with histologic subtype of renal cell carcinoma (Rasmuson et al 1996).…”

Section: B2-msupporting

confidence: 88%

The serum levels of soluble interleukin-2 receptor α and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas

Bień

Rąpała

Krawczyk

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

sIL-2R alpha and LDH were [corrected] proven to be promising markers [corrected] for diagnosis and treatment monitoring in children with STS. The markers [corrected] correlated also with some [corrected] important prognostic clinico-pathological factors for childhood [corrected] STS; however, they [corrected] failed to predict EFS and OS. Measurements of serum [corrected] B2-M were shown [corrected] to have no clinical value in the diagnostics, prognostics and treatment monitoring in paediatric STS.

show abstract

Section: B2-msupporting

confidence: 88%

The serum levels of soluble interleukin-2 receptor α and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas

Bień

Rąpała

Krawczyk

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…We have identified one of the 13 proteomic features most strongly associated with HCC as b2-microglobulin. This is a particularly reassuring finding since b2-microglobulin has previously been shown (using immunoturbometric methods) to be markedly elevated in the serum of hepatitis C patients with HCVrelated HCC when compared to HCV positive patients without HCC (36716.5 mg ml À1 vs 2.370.8 mg ml À1 ; Po0.0001) or healthy subjects (1.670.4 mg ml À1 ; Po0.0001) (Malaguarnera et al, 2000). However, it is unlikely that b2-microglobulin alone could act as a biomarker specifically for HCC as serum levels of b2-microglobulin are also elevated in patients with chronic inflammatory disease, viral disease (e.g.…”

Section: Discussionmentioning

confidence: 58%

Preclinical and post-treatment changes in the HCC-associated serum proteome

et al. 2006

View full text Add to dashboard Cite

SELDI-based proteomic profiling of body fluids is currently in widespread use for cancer biomarker discovery. We have successfully used this technology for the diagnosis of hepatocellular carcinoma (HCC) in hepatitis C patients and now report its application to serial serum samples from 37 hepatitis C patients before development of HCC, with HCC and following radiofrequency ablation of the tumour. As with alpha-fetoprotein, an accepted biomarker for HCC, we hypothesised that HCC-associated proteomic features would 'return to normal' following successful treatment and the primary aim of our study was to test this hypothesis. Several SELDI peaks that changed significantly during HCC development were detected but they did not reverse following treatment. These data may be interpreted to suggest that the characteristic SELDI profile is not linearly related to tumour burden but may result from the progression of underlying liver disease or from the emergence of precancerous lesions. b2-Microglobulin, a protein previously reported to be markedly elevated in patients with HCV related HCC, was also the most significantly HCC associated proteomic feature (m/z 11720) in this study.

show abstract

“…Thus, in 50 cases with chronic hepatitis C plus hepatocellular carcinoma, in 50 cases of chronic hepatitis C and in 20 cases of control group serum β 2 -MG levels are assessed and the results are compared with alpha-fetoprotein (AFP) levels, and tomographic, ultrasonographic findings and significant elevations are seen in the serum β 2 -MG levels when related to the AFP levels. In addition, a positive relation is seen between serum β 2 -MG levels; AFP level and the tumor mass (Malaguarnera et al 2000).…”

Section: Discussionmentioning

confidence: 83%